Endogenous peptide
Urotensin II-related peptide
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Urotensin II-related peptide →Peptide directory
Find a peptide
Public profiles inside a larger governed registry
Search by peptide name, brand, or research code. Open a full evidence profile or the published sources available for a record still in development. Source publication does not mean a completed scientific appraisal.
The registry is an expanding catalog, not a complete list of every peptide. A missing public result does not mean no research exists.
Published profiles
Search profiles and sources
Glycopeptide antibiotic
Vancomycin
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Vancomycin →- Developing
Arginine vasopressin, also called argipressin or antidiuretic hormone, is an endogenous cyclic nonapeptide synthesized in hypothalamic neurons and released from the posterior pituitary. V1a-receptor activation constricts vascular smooth muscle, V2-receptor activation promotes renal water reabsorption through aquaporin-2 trafficking, and additional receptor signaling contributes to pituitary, hemostatic, and central effects. Pharmaceutical vasopressin is used in tightly defined clinical contexts, notably as an intravenous vasopressor for vasodilatory shock in the United States; endogenous physiology, diagnostic biomarkers, receptor antagonists, analogs, and investigational intranasal research must remain distinct.
Evidence and record details
Evidence integrity map
Human 1Preclinical 0Durable IDs 7Open signals 1- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Synthetic peptide
Vesugen
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Vesugen →Synthetic dipeptide
Vilon
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Vilon →Cyclic peptide analog
Voclosporin
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Voclosporin →C-type natriuretic peptide analog
Vosoritide
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Vosoritide →- Emerging
Ziconotide is a conotoxin-derived peptide studied for pain through N-type calcium-channel modulation. Evidence for a defined clinical preparation and route must be separated from broad conotoxin research and animal experiments.
Evidence and record details
Evidence integrity map
Human 0Preclinical 0Durable IDs 6Open signals 1- Publication state
- Published profile
- Verified source records
- 153 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Cyclic peptide therapeutic
Zilucoplan
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Zilucoplan →
How the public directory relates to the 500-record Master Registry
master registry transparency
500 master records, with governance status shown explicitly
501
Master records
467
Governed records
34
Review-deferred
458
Peptide acquisition eligible
9
Governed comparators
The master registry has 467 governed identities from 501 records. 34 remain review-gated. Nine governed records are scientific comparators, leaving 458 peptide identities in the source acquisition cohort. Database reconciliation is a separate step. The 51 profiles shown on this directory are a represented public-profile subset, not the size of the master registry. All 51 public profiles on this render reconcile to governed peptide identities in that registry; unknown, duplicate, deferred, or comparator identities fail closed instead of appearing publicly.
Explore the full Master Registry →What the profile status labels mean
Evidence, chemistry, and regulatory counts include only records that crossed the relevant public-publication gate. A zero means none published in that lane—not that nothing is known. “No governed record published” is a publication-state disclosure; internal or pending material may exist without appearing in public counts. Source verification, editorial publication, and accountable scientific appraisal are distinct states; a source count alone does not approve a scientific conclusion.
Recently updated public records
When each public profile record was last changed — not clinical or scientific activity.